RecruitingPhase 1Phase 2NCT06697197
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
Sponsor
Bristol-Myers Squibb
Enrollment
413 participants
Start Date
Feb 17, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant.
- Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF.
Exclusion Criteria2
- History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures.
- Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBMS-986482
Specified dose on specified days
DRUGNivolumab and rHuPH20
Specified dose on specified days
DRUGNivolumab/relatlimab/rHuPH20
Specified dose on specified days
DRUGBevacizumab
Specified dose on specified days
Locations(21)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06697197
Related Trials
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
NCT070609892 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
NCT0585336725 locations
Study of CM518D1 in Patients With Advanced Solid Tumors
NCT070197791 location
A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.
NCT076484721 location